$72.035
0.865[1.22%]
Last update: 2:53PM Get Real Time Here
Axsome Therapeutics
(NASDAQ:AXSM)Axsome Therapeutics Stock (NASDAQ:AXSM), Analyst Ratings, Price Targets, Predictions
Axsome Therapeutics Inc has a consensus price target of $110.42, established from looking at the 87 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, HC Wainwright & Co., and Mizuho on April 10, 2024, April 2, 2024, and March 28, 2024. With an average price target of $135.33 between Cantor Fitzgerald, HC Wainwright & Co., and Mizuho, there's an implied 87.87% upside for Axsome Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Mizuho
Truist Securities
RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Axsome Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 48.54% | Cantor Fitzgerald | Charles Duncan | → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 04/02/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 163.76% | HC Wainwright & Co. | Raghuram Selvaraju | $190 → $190 | Maintains | Buy | Get Alert |
| 03/28/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 51.32% | Mizuho | Graig Suvannavejh | $108 → $109 | Maintains | Buy | Get Alert |
| 03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 108.23% | Truist Securities | Joon Lee | → $150 | Maintains | Buy | Get Alert |
| 03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 77.69% | RBC Capital | Leonid Timashev | $123 → $128 | Maintains | Outperform | Get Alert |
| 03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 76.3% | Citigroup | David Hoang | $125 → $127 | Maintains | Buy | Get Alert |
| 03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 163.76% | HC Wainwright & Co. | Raghuram Selvaraju | $180 → $190 | Maintains | Buy | Get Alert |
| 03/20/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 149.88% | HC Wainwright & Co. | Raghuram Selvaraju | → $180 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 49.93% | Baird | Joel Beatty | → $108 | Initiates | → Outperform | Get Alert |
| 03/04/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 149.88% | HC Wainwright & Co. | Raghuram Selvaraju | → $180 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 49.93% | Mizuho | Graig Suvannavejh | $112 → $108 | Maintains | Buy | Get Alert |
| 02/21/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 73.53% | Guggenheim | Yatin Suneja | $110 → $125 | Maintains | Buy | Get Alert |
| 02/21/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 70.75% | RBC Capital | Leonid Timashev | $126 → $123 | Maintains | Outperform | Get Alert |
| 02/21/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 42.99% | Cantor Fitzgerald | Charles Duncan | $108 → $103 | Maintains | Overweight | Get Alert |
| 02/20/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 49.93% | Cantor Fitzgerald | Charles Duncan | → $108 | Reiterates | Overweight → Overweight | Get Alert |
| 02/16/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 55.48% | Mizuho | Graig Suvannavejh | $90 → $112 | Maintains | Buy | Get Alert |
| 02/06/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 54.09% | UBS | Ashwani Verma | → $111 | Initiates | → Buy | Get Alert |
| 01/25/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 74.91% | RBC Capital | Leonid Timashev | → $126 | Initiates | → Outperform | Get Alert |
| 01/22/2024 | AXSM | Buy Now | Axsome Therapeutics | $72.03 | 49.93% | Cantor Fitzgerald | Charles Duncan | → $108 | Reiterates | Overweight → Overweight | Get Alert |
FAQ
What is the target price for Axsome Therapeutics (AXSM)?
The latest price target for Axsome Therapeutics (NASDAQ: AXSM) was reported by Cantor Fitzgerald on April 10, 2024. The analyst firm set a price target for $107.00 expecting AXSM to rise to within 12 months (a possible 48.54% upside). 43 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Axsome Therapeutics (AXSM)?
The latest analyst rating for Axsome Therapeutics (NASDAQ: AXSM) was provided by Cantor Fitzgerald, and Axsome Therapeutics reiterated their overweight rating.
When was the last upgrade for Axsome Therapeutics (AXSM)?
The last upgrade for Axsome Therapeutics Inc happened on August 8, 2023 when B of A Securities raised their price target to $81. B of A Securities previously had an underperform for Axsome Therapeutics Inc.
When was the last downgrade for Axsome Therapeutics (AXSM)?
The last downgrade for Axsome Therapeutics Inc happened on August 10, 2021 when Morgan Stanley changed their price target from $105 to $34 for Axsome Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Axsome Therapeutics (AXSM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Axsome Therapeutics (AXSM) correct?
While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a reiterated with a price target of $0.00 to $107.00. The current price Axsome Therapeutics (AXSM) is trading at is $72.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.